Ashton Thomas Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Ashton Thomas Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53M	Buy	3,091 +43	+1%	+$19.1K	0.23%	101
2026 Q1	$1.36M	Buy	3,048 +146	+5%	+$68.1K	0.17%	136
2025 Q4	$1.32M	Sell	2,902 -79	-3%	-$34.1K	0.25%	89
2025 Q3	$1.17M	Sell	2,981 -710	-19%	-$297K	0.16%	136
2025 Q2	$1.64M	Buy	3,691 +12	+0.3%	+$5.53K	0.4%	69
2025 Q1	$1.78M	Buy	3,679 +435	+13%	+$203K	0.49%	57
2024 Q4	$1.31M	Buy	3,244 +55	+2%	+$25.5K	0.36%	66
2024 Q3	$1.48M	Buy	3,189 +188	+6%	+$90.3K	0.29%	83
2024 Q2	$1.46M	Buy	+3,001	New	+$1.3M	0.35%	75

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ashton Thomas Securities's VRTX Position: Q2 2026 in Review

Ashton Thomas Securities increased its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q2 2026, buying an estimated $19.1K and bringing the position to 3,091 shares worth $1.53M. The position accounts for 0.23% of the portfolio, ranked #101.

Ashton Thomas Securities first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.78M in Q1 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Ashton Thomas Securities held 3,091 shares of Vertex Pharmaceuticals worth $1.53M as of Q2 2026.
Ashton Thomas Securities bought 43 Vertex Pharmaceuticals shares in Q2 2026, an estimated $19.1K.
Vertex Pharmaceuticals made up 0.23% of Ashton Thomas Securities's portfolio in Q2 2026, its #101 holding.
Ashton Thomas Securities first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Ashton Thomas Securities's Vertex Pharmaceuticals position peaked at $1.78M in Q1 2025.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ashton Thomas Securities's 13F filing for Q2 2026, filed 27 Jul 2026.